Earnings call transcript: Elite Pharma's Q3 2024 revenue dips 8%, stock falls 9.96%
Elite Pharmaceuticals, with a market capitalization of $531 million, reported a decline in third-quarter revenue for 2024, falling 8% from the previous year. Despite a strong nine-month performance, ...
Why Recursion Pharmaceuticals Stock Is Soaring Today
Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
BioSpace7d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Seeking Alpha14d
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Vertex Pharmaceuticals continues to execute ... conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share. As of yesterday evening, the FDA ...
Benzinga.com14d
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
Now Read: Purdue Pharma, Sackler Family To Pay $7.4 Billion In Settlement Over OxyContin That Fueled ‘Devastating’ Opioid Epidemic Government surveys show analgesics, or medications that ...
Investopedia14d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
Vertex set the U.S. wholesale price of Journavx at $15.50 per 50mg pill. Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved ...
BioSpace14d
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
MarketWatch14d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...
Business Insider15d
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.
The Indianapolis Star15d
Indiana basketball vs Purdue final score: Boilermakers beat Hoosiers at Mackey Arena
The Purdue and Indiana men's basketball teams faced off on Friday night with the Boilermakers coming away with an 81-76 win at Mackey Arena. There were 15 lead changes. Purdue wins No. 17 for the ...
Eagle-Tribune16d
Our View: Sacklers owe more than money for the opioid crisis
The recent settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is a welcome ...